-
satisfaction
100%
-
People worldwide
70k -
Countries we operate in
>75k -
Manufacturing sites
37
-
R&D investment in 2023 (£)
6.2bn -
4
Global R&D in US, UK, Belgium and Italy
-
6
Major business development deals in 2023
-
Packs of medicines and doses of vaccines delivered
2.3bn -
Vaccine and medicine sales in 2023 (£)
30.3bn -
Sales of products launched in the last 5 years including lifecycle innovation (£)
10.0bn -
Sales growth in 2023
14%
-
Packs of medicines and doses of vaccines delivered
2.3bnworldwide
-
Vaccine and medicine sales in 2023 (£)
30.3bnacross the globe
-
Sales of products launched in the last 5 years including lifecycle innovation (£)
10.0bnfigure support text
-
Sales growth in 2023
14%
-
In the Access to Medicine Index
1st -
In our industry for the S&P Global Corporate Sustainability Assessment
1st -
Global Health pipeline assets progressed to address priority WHO Diseases
12 -
Reduction in Operational Carbon emissions
10%
Performance
-
People worldwide
70kAt gravida molestie sodales sed duis aliquam at duis tristique.
-
Countries we operate in
>75Lorem ipsum dolor
-
37.3bn
profit made
-
37
Manufacturing sites
Performance
-
People worldwide
70kAt gravida molestie sodales sed duis aliquam at duis tristique.
-
Countries we operate in
>75Lorem ipsum dolor
- 37.3bn
-
Manufacturing sites
37
test
card 3
Title
Culture module
